Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Lancet. Neurology|July 19, 2025
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension studyAmit Bar-Or, Michal Dufek, Hrvoje Budincevic, et al.
Archives of Neurology|November 11, 2009
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosisBryn M Burkholder, Benjamin Osborne, Michael J Loguidice, et al.
Science Translational Medicine|May 27, 2021
Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupusJodi L Karnell, Yanping Wu, Nanette Mittereder, et al.
Brain : a Journal of Neurology|January 22, 2011
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomographyShiv Saidha, Stephanie B Syc, Mohamed A Ibrahim, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Sean J Pittock, Friedemann Paul, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2021
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSDBruce Ac Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Annals of Clinical and Translational Neurology|March 9, 2019
Retinal measurements predict 10-year disability in multiple sclerosisAlissa Rothman, Olwen C Murphy, Kathryn C Fitzgerald, et al.
JAMA Neurology|January 16, 2013
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosisShiv Saidha, Elias S Sotirchos, Jiwon Oh, et al.
Lancet (London, England)|September 10, 2019
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 27, 2021
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Jeffrey L Bennett, Ho Jin Kim, et al.
Pageof 4